![Enrique Poradosu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Enrique Poradosu
Gründer bei
NUVECTIS PHARMA, INC.
Vermögen: 18 Mio $ am 31.05.2026
Profil
Dr. Enrique Poradosu is a Chief Scientific & Business Officer, Executive VP at Nuvectis Pharma, Inc. Dr. Poradosu was previously employed as a Senior VP-Business & Scientific Strategy by Stemline Therapeutics, Inc. and a Vice President-Business & Scientific Strategy by Keryx Biopharmaceuticals, Inc. He received his undergraduate degree from The Hebrew University of Jerusalem and a doctorate degree from The Hebrew University of Jerusalem.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NUVECTIS PHARMA, INC. 6,81 % | 13.04.2026 | 1.806.319 ( 6,81 % ) | 18 Mio $ | 31.05.2026 |
Aktive Positionen von Enrique Poradosu
| Unternehmen | Position | Beginn |
|---|---|---|
| NUVECTIS PHARMA, INC. | Gründer | 27.07.2020 |
Ehemalige bekannte Positionen von Enrique Poradosu
| Unternehmen | Position | Ende |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2020 |
| KERYX BIOPHARMACEUTICALS | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2016 |
Ausbildung von Enrique Poradosu
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
37
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel oncology therapeutics | Health Technology |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nuvectis Pharma, Inc.
 Nuvectis Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer | Health Technology |
